The above studies suggest that a high BCL2/BCL2L1 mRNA ratio correlates with response to venetoclax in MM patients, indicating the importance of examining not only BCL2 but rather the ratio between BCL2 and BCL2L1 in AL patients with t(11;14) in order to decide on treatment strategies. The gene discussed is BCL2L1; the disease is Miyoshi myopathy.